After the 12-week Maintenance and Extension study period (Day 112 to Day 196) where all treatment groups discontinued semaglutide, the placebo monotherapy group regained 43% of body weight that ...

After the 12-week Maintenance and Extension study period (Day 112 to Day 196) where all treatment groups discontinued semaglutide, the placebo monotherapy group regained 43% of body weight that ...

In the enobosarm 3mg + semaglutide group, only 16% of patients had at least a 10% decline in stair climb power at 16 weeks, representing a 62.4% relative reduction of patients with a ≥10% ...

The enobosarm 3mg + semaglutide group had the added benefit of fewer AEs reported for certain gastrointestinal side effects (Diarrhea, Nausea, and Gastroesophageal Reflux Disease) compared to ...

--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY ...

--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY ...

The enobosarm 3mg + semaglutide was the best dose with a >99% mean relative reduction in loss of lean mass (p <0.001).

In the enobosarm 3mg + semaglutide group, only 16% of patients had at least a 10% decline in stair climb power at 16 weeks, representing a 62.4% relative reduction of patients with a ≥10% ...

The mean duration of exposure to semaglutide or placebo in the overall trial population was 34.2±13.7 months (33.3±14.4 months for semaglutide and 35.1±13.0 months for placebo); patients ...

--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial ...